Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Structural Heart Disease: Innovation, Implementation & Interdisciplinary Care, 8/20/2021 8:00:00 AM - 8/20/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenters
Terrence D. Welch, MD, FACC, FASE
Associate Professor of Medicine, Geisel School of Medicine at Dartmouth
Director, Cardiovascular Fellowship Program
Section of Cardiovascular Medicine
Dartmouth-Hitchcock Medical Center
Michael N. Young, MD, RPVI
Assistant Professor of Medicine, Geisel School of Medicine at Dartmouth
Director, Structural Heart Disease Program
Section of Cardiovascular Medicine
Dartmouth-Hitchcock Medical Center
About our Presenters
Dr. Terrence Welch completed his undergraduate work at the University of Notre Dame and medical school at Washington University School of Medicine He completed post-graduate training in internal medicine at the University of Michigan and in cardiovascular diseases at the Mayo Clinic. He is board certified in Internal Medicine, Cardiovascular Disease, and Echocardiography. His practice interests include echocardiography, structural heart disease, heart failure, and pericardial disease. He is the currently the Program Director for the Cardiovascular Medicine Fellowship and the Medical Director of the Cardiac Rehabilitation program.
Dr. Michael Young received his undergraduate degree from the University of Louisville, majoring in Biology, Chemistry, and Psychology. He then matriculated to Vanderbilt University for medical school, and stayed on at Vanderbilt for both internal medicine residency and cardiology fellowship training. Dr. Young pursued his advanced interventional cardiology training at the Massachusetts General Hospital, where he graduated from the Coronary Vascular Medicine and Structural Heart Disease advanced fellowship programs. In complement to his clinical interests, Dr. Young maintains a keen interest in healthcare delivery science, policy, and outcomes-based research.
Learning Outcome(s)
Participants will be able to review the Multidisciplinary Heart Team approach for the management of structural heart disease entities and the landmark trial data that have expanded the indications for percutaneous valve therapies in contemporary practice.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenters
Terrence D. Welch, MD, FACC, FASE
Associate Professor of Medicine, Geisel School of Medicine at Dartmouth
Director, Cardiovascular Fellowship Program
Section of Cardiovascular Medicine
Dartmouth-Hitchcock Medical Center
Michael N. Young, MD, RPVI
Assistant Professor of Medicine, Geisel School of Medicine at Dartmouth
Director, Structural Heart Disease Program
Section of Cardiovascular Medicine
Dartmouth-Hitchcock Medical Center
About our Presenters
Dr. Terrence Welch completed his undergraduate work at the University of Notre Dame and medical school at Washington University School of Medicine He completed post-graduate training in internal medicine at the University of Michigan and in cardiovascular diseases at the Mayo Clinic. He is board certified in Internal Medicine, Cardiovascular Disease, and Echocardiography. His practice interests include echocardiography, structural heart disease, heart failure, and pericardial disease. He is the currently the Program Director for the Cardiovascular Medicine Fellowship and the Medical Director of the Cardiac Rehabilitation program.
Dr. Michael Young received his undergraduate degree from the University of Louisville, majoring in Biology, Chemistry, and Psychology. He then matriculated to Vanderbilt University for medical school, and stayed on at Vanderbilt for both internal medicine residency and cardiology fellowship training. Dr. Young pursued his advanced interventional cardiology training at the Massachusetts General Hospital, where he graduated from the Coronary Vascular Medicine and Structural Heart Disease advanced fellowship programs. In complement to his clinical interests, Dr. Young maintains a keen interest in healthcare delivery science, policy, and outcomes-based research.
Learning Outcome(s)
Participants will be able to review the Multidisciplinary Heart Team approach for the management of structural heart disease entities and the landmark trial data that have expanded the indications for percutaneous valve therapies in contemporary practice.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
